Rieko Ishima

Dr. Rieko Ishima

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 1999 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
RIRieko Ishima
Rieko Ishima
JLJohn M. Louis
John M. Louis
DTDennis A. Torchia
Dennis A. Torchia

17 April 2012 in Journal of Chemical Theory and Computation
Verified
Journal Article
Closed access
YCYufeng Cai
Yufeng Cai
NYNese Kurt Yilmaz
Nese Kurt Yilmaz
WMWazo Myint
Wazo Myint
RIRieko Ishima
Rieko Ishima
CSCelia Schiffer
Celia Schiffer

21 August 2019 in Journal of Biomolecular NMR
Verified
Journal Article
Closed access
PDF file
MLManman Lu
Manman Lu
RIRieko Ishima
Rieko Ishima
TPTatyana Polenova
Tatyana Polenova
AGAngela M. Gronenborn
Angela M. Gronenborn

19 October 2012 in Biology
Verified
Journal Article
Open access
PDF file
Tatiana IlinaTatiana Ilina
Tatiana Ilina
KLKrystal LaBarge
Krystal LaBarge
SSStefan Sarafianos
Stefan Sarafianos
RIRieko Ishima
Rieko Ishima
MPMichael Parniak
Michael Parniak
HIV-1 enzyme reverse transcriptase (RT) is a major target for antiviral drug development, with over half of current FDA-approved therapeutics against HIV infection targeting the DNA polymerase activity of this enzyme. HIV-1 RT is a multifunctional enzyme that has RNA and DNA dependent polymerase activity, along with ribonuclease H (RNase H) activity. The latter is responsible for degradation of the viral genomic RNA template during first strand DNA synthesis to allow completion of reverse transcription and the viral dsDNA. While the RNase H activity of RT has been shown to be essential for virus infectivity, all currently used drugs directed at RT inhibit the polymerase activity of the enzyme; none target RNase H. In the last decade, the increasing prevalence of HIV variants resistant to clinically used antiretrovirals has stimulated the search for inhibitors directed at stages of HIV replication different than those targeted by current drugs. HIV RNase H is one such novel target and, over the past few years, significant progress has been made in identifying and characterizing new RNase H inhibitor pharmacophores. In this review we focus mainly on the most potent low micromolar potency compounds, as these provide logical bases for further development. We also discuss why HIV RNase H has been a difficult target for antiretroviral drug development.

29 November 2010 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
QGQingguo Gong
Qingguo Gong
LMLakshmi Menon
Lakshmi Menon
TITatiana Ilina
Tatiana Ilina
LMLena G. Miller
Lena G. Miller
JAJinwoo Ahn
Jinwoo Ahn
RIRieko Ishima
Rieko Ishima

31 July 2012 in Chemical Biology & Drug Design
Verified
Journal Article
Open access
PDF file
MCMartin T. Christen
Martin T. Christen
LMLakshmi Menon
Lakshmi Menon
NMNataliya S. Myshakina
Nataliya S. Myshakina
JAJinwoo Ahn
Jinwoo Ahn
MPMichael A. Parniak
Michael A. Parniak
RIRieko Ishima
Rieko Ishima
HIV‐1 reverse transcriptase (RT) has been an attractive target for the development of antiretroviral agents. Although this enzyme is bi‐functional, having both DNA polymerase and ribonuclease H (RNH) activities, there is no clinically approved inhibitor of the RNH activity. Here, we characterize the structural basis and molecular interaction of an allosteric site inhibitor, BHMP07, with the wild‐type (WT) RNH fragment. Solution NMR experiments for inhibitor titration on WT RNH showed relatively wide chemical shift perturbations, suggesting a long‐range conformational effect on the inhibitor interaction. Comparisons of the inhibitor‐induced NMR chemical shift changes of RNH with those of RNH dimer, in the presence and absence of Mg2+, were performed to determine and verify the interaction site. The NMR results, with assistance of molecular docking, indicate that BHMP07 preferentially binds to a site that is located between the RNH active site and the region encompassing helices B and D (the ‘substrate‐handle region’). The interaction site is consistent with the previous proposed site, identified using a chimeric RNH (p15‐EC) [Gong et al. (2011) Chem Biol Drug Des 77, 39–47], but with slight differences that reflect the characteristics of the amino acid sequences in p15‐EC compared to the WT RNH.